Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. Continue reading this article with a Barron’s subscription. View Options Source link
Read more Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 BillionBy Anthony O. Goriainoff AstraZeneca said Thursday that its and MSD’s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic castration-resistant prostate cancer,…
Read more AstraZeneca Says US Approved Lynparza as a Prostate Cancer TreatmentBy Joe Hoppe AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter’s baxdrostat cardiorenal drug for an upfront…
Read more AstraZeneca PLC Will Buy CinCor for Cardiorenal AssetAstraZeneca PLC ADR AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. It focuses on the discovery, development, and commercialization…
Read more AZN Stock Price | AstraZeneca PLC ADR Stock Quote (U.S.: Nasdaq) | MarketWatchHospitalizations are rising again in New York City with the spread of new COVID-19 subvariants that are better at evading immunity. Cases of flu and respiratory syncytial virus,…
Read more Hospitalizations on the rise in New York City as new COVID strains spread rapidly
